Hodgkin's lymphoma

[Blood] The authors showed that late-stage Non-Hodgkin's Lymphoma was resistant to therapy targeting phagocytosis checkpoint CD47, due to the compromised capacity of tumor-associated macrophages to phagocytose lymphoma cells.

[Scientific Reports] MYC+ cells accounted for 21% and 18% of CD68+ and CD163+ cells, respectively. Numbers of MYC− macrophages were significantly higher in EBV+ cases while no differences were observed for MYC+ macrophages between EBV+ and EBV− cases.